CoChat
Sign Up
Cited by 527

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Molecular mechanisms of tumor resistance to radiotherapy

Wu, Yu, Song, Yingqiu, Wang, Runze, Wang, Tianlu·2023·Molecular Cancer
DOI 10.1186/s12943-023-01801-2PMC PMC10268375
Open this paper in CoChat — free account

Abstract

Background: Cancer is the most prevalent cause of death globally, and radiotherapy is considered the standard of care for most solid tumors, including lung, breast, esophageal, and colorectal cancers and glioblastoma. Resistance to radiation can lead to local treatment failure and even cancer recurrence. Main body: In this review, we have extensively discussed several crucial aspects that cause resistance of cancer to radiation therapy, including radiation-induced DNA damage repair, cell cycle arrest, apoptosis escape, abundance of cancer stem cells, modification of cancer cells and their microenvironment, presence of exosomal and non-coding RNA, metabolic reprogramming, and ferroptosis. We aim to focus on the molecular mechanisms of cancer radiotherapy resistance in relation to these aspects and to discuss possible targets to improve treatment outcomes. Conclusions: Studying the molecular mechanisms responsible for radiotherapy resistance and its interactions with the tumor environment will help improve cancer responses to radiotherapy. Our review provides a foundation to identify and overcome the obstacles to effective radiotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-023-01801-2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The multiple pathways for DNA damage repair, cell cycle arrest, and apoptosis escape after radiation therapy. Key regulators in the DNA damage repair pathway may alter sensitivity to radiotherapy in cancer cells, whereas cell cycle checkpoints may respond to damage when tumor cells are exposed to ionizing radiation, thus causing cell cycle arrest and allowing more time for repair, which increases resistance to radiotherapy. If DNA damage repair is unsuccessful, apoptotic signaling pathways are induced to resist radiotherapy damage. HR: homologous recombination, NHEJ: non-homologous end joining, BER: base excision repair DSBs: double-strand breaks, SSBs: single-strand breaks, ATM: ataxia-telangiectasia mutated, ATR: ATM and Rad3-related kinase, DNA-PKcs: DNA-dependent protein kinase, MRN: Mre11–Rad50–NBS1, RPA: replication protein A, DNA-PKcs: DNA-dependent protein kinase catalytic subunit, CHK1: checkpoint kinase 1, CHK2: checkpoint kinase 2, PARP: poly(ADP-ribose) polymerase, XRCC4: X-ray repair cross-complementing protein 4, XLF:XRCC4-like factor, PAXX: Paralogue of XRCC4 and XLF, LIG4: DNA ligase IV, MDC1: mediator of DNA damage checkpoint protein 1, CAD: caspase-activated DNase, ICAD: inhibitor of CAD, MDM2: mouse double minute 2 homolog, FBXW7: F-box and WD repeat domain-containing 7, BCL-2: B-cell lymphoma 2
Fig. 1 The multiple pathways for DNA damage repair, cell cycle arrest, and apoptosis escape after radiation therapy. Key regulators in the DNA damage repair pathway may alter sensitivity to radiotherapy in cancer cells, whereas cell cycle checkpoints may respond to damage when tumor cells are exposed to ionizing radiation, thus causing cell cycle arrest and allowing more time for repair, which increases resistance to radiotherapy. If DNA damage repair is unsuccessful, apoptotic signaling pathways are induced to resist radiotherapy damage. HR: homologous recombination, NHEJ: non-homologous end joining, BER: base excision repair DSBs: double-strand breaks, SSBs: single-strand breaks, ATM: ataxia-telangiectasia mutated, ATR: ATM and Rad3-related kinase, DNA-PKcs: DNA-dependent protein kinase, MRN: Mre11–Rad50–NBS1, RPA: replication protein A, DNA-PKcs: DNA-dependent protein kinase catalytic subunit, CHK1: checkpoint kinase 1, CHK2: checkpoint kinase 2, PARP: poly(ADP-ribose) polymerase, XRCC4: X-ray repair cross-complementing protein 4, XLF:XRCC4-like factor, PAXX: Paralogue of XRCC4 and XLF, LIG4: DNA ligase IV, MDC1: mediator of DNA damage checkpoint protein 1, CAD: caspase-activated DNase, ICAD: inhibitor of CAD, MDM2: mouse double minute 2 homolog, FBXW7: F-box and WD repeat domain-containing 7, BCL-2: B-cell lymphoma 2CC BY · PubMed Central
Fig. 2 The development of radioresistance in the tumor microenvironment after radiation. Radiation can induce hypoxia, fibrosis, vascular damage, chronic inflammation, and immunosuppression in the tumor microenvironment, all of which may lead to RT resistance. Cancer-associated fibroblasts are also important aspects of the tumor microenvironment for the generation of radioresistance because they affect immune cells in such a way that leads to immunosuppression, fibrosis, and extracellular matrix remodeling. RT: radiation therapy, ROS: reactive oxygen species, GSH: glutathione, VEGF: vascular endothelial growth factor, Treg: regulatory T cells, NK: natural killer cells, DC: dendritic cells, CAF: tumor-associated fibroblasts, MDSCs: bone-marrow-derived suppressor cells, ECM: extracellular matrix, IL-1α: interleukin-1α, HIF-1α: hypoxia-inducible factor 1α, PDGF: Platelet-derived growth factor, CSC: Cancer stem cell, NADPH: nicotinamide adenine dinucleotide phosphate oxidase, TGF-β: transforming growth factor-β, CHK1: checkpoint kinase 1, CHK2: checkpoint kinase 2, cGAS: cyclic GMP-AMP synthase, STING: stimulator of interferon genes, IFN: interferon, PD‑L1: programmed cell death 1 ligand 1, IL‑10: interleukin 10, ICD: immunogenic cell death
Fig. 2 The development of radioresistance in the tumor microenvironment after radiation. Radiation can induce hypoxia, fibrosis, vascular damage, chronic inflammation, and immunosuppression in the tumor microenvironment, all of which may lead to RT resistance. Cancer-associated fibroblasts are also important aspects of the tumor microenvironment for the generation of radioresistance because they affect immune cells in such a way that leads to immunosuppression, fibrosis, and extracellular matrix remodeling. RT: radiation therapy, ROS: reactive oxygen species, GSH: glutathione, VEGF: vascular endothelial growth factor, Treg: regulatory T cells, NK: natural killer cells, DC: dendritic cells, CAF: tumor-associated fibroblasts, MDSCs: bone-marrow-derived suppressor cells, ECM: extracellular matrix, IL-1α: interleukin-1α, HIF-1α: hypoxia-inducible factor 1α, PDGF: Platelet-derived growth factor, CSC: Cancer stem cell, NADPH: nicotinamide adenine dinucleotide phosphate oxidase, TGF-β: transforming growth factor-β, CHK1: checkpoint kinase 1, CHK2: checkpoint kinase 2, cGAS: cyclic GMP-AMP synthase, STING: stimulator of interferon genes, IFN: interferon, PD‑L1: programmed cell death 1 ligand 1, IL‑10: interleukin 10, ICD: immunogenic cell deathCC BY · PubMed Central
Fig. 3 The mechanisms by which cancer stem cells generate radioresistance. This diagram shows how CSCs can self-renew upon differentiation, become quiescent, be involved in tumorigenesis, and generate immunosuppressive signals as well as exert possible effects of DNA damage repair, low ROS levels, apoptosis, autophagy, and epithelial–mesenchymal transitions in tumor stem cell–associated radioresistance. In addition, several active signaling pathways (e.g., Wnt Notch Hedgehog TGF-ß PI3K/AKT/mTOR) may also be closely related to tumor stem cell radioresistance. EMT: epithelial–mesenchymal transition, ROS: reactive oxygen species, TGF-β: transforming growth factor-β, PD-L1: programmed cell death ligand 1, IL-10: interleukin 10, Bcl-2: B-cell lymphoma-2
Fig. 3 The mechanisms by which cancer stem cells generate radioresistance. This diagram shows how CSCs can self-renew upon differentiation, become quiescent, be involved in tumorigenesis, and generate immunosuppressive signals as well as exert possible effects of DNA damage repair, low ROS levels, apoptosis, autophagy, and epithelial–mesenchymal transitions in tumor stem cell–associated radioresistance. In addition, several active signaling pathways (e.g., Wnt Notch Hedgehog TGF-ß PI3K/AKT/mTOR) may also be closely related to tumor stem cell radioresistance. EMT: epithelial–mesenchymal transition, ROS: reactive oxygen species, TGF-β: transforming growth factor-β, PD-L1: programmed cell death ligand 1, IL-10: interleukin 10, Bcl-2: B-cell lymphoma-2CC BY · PubMed Central
Fig. 4 The relationship between metabolic reprogramming and radioresistance. Active glycolysis and lipid metabolism, which are typical of cancer metabolism, promote the development of radioresistance by mediating the development of immunosuppressive microenvironments and blocking apoptosis. In addition, the high expression of glutamine synthetase, purines, and serine protease inhibitor E2 can promote DNA damage repair, thereby leading to radioresistance. FAO: fatty acid oxidation, FFA: free fatty acid, Glu; glucose, G6P: glucose-6-phosphate, G3P: glyceraldehyde triphosphate, DHAP: dihydroxyacetone phosphate, FBP: fructose-1,6-bisphosphate, GS: glutamine synthetase, ATM: ataxia-telangiectasia mutated, NF-κB: nuclear factor-kappa B, Cyt c: cytochrome c, HK2: hexokinase 2, PFK1: phosphofructokinase 1, MDSCs: myeloid-derived suppressor cells, DHAP: dihydroxyacetone phosphate, HIF-1α: hypoxia-inducible factor 1α, SERPINE2: serine protease inhibitor E2, TCA cycle: tricarboxylic acid cycle
Fig. 4 The relationship between metabolic reprogramming and radioresistance. Active glycolysis and lipid metabolism, which are typical of cancer metabolism, promote the development of radioresistance by mediating the development of immunosuppressive microenvironments and blocking apoptosis. In addition, the high expression of glutamine synthetase, purines, and serine protease inhibitor E2 can promote DNA damage repair, thereby leading to radioresistance. FAO: fatty acid oxidation, FFA: free fatty acid, Glu; glucose, G6P: glucose-6-phosphate, G3P: glyceraldehyde triphosphate, DHAP: dihydroxyacetone phosphate, FBP: fructose-1,6-bisphosphate, GS: glutamine synthetase, ATM: ataxia-telangiectasia mutated, NF-κB: nuclear factor-kappa B, Cyt c: cytochrome c, HK2: hexokinase 2, PFK1: phosphofructokinase 1, MDSCs: myeloid-derived suppressor cells, DHAP: dihydroxyacetone phosphate, HIF-1α: hypoxia-inducible factor 1α, SERPINE2: serine protease inhibitor E2, TCA cycle: tricarboxylic acid cycleCC BY · PubMed Central
Fig. 5 The role of exosomes in cancer radiotherapy resistance. Radiation-induced paracrine effects mediated by exosomes and their contents (e.g., exosomal proteins and non-coding RNAs) affect radiotherapy efficacy via different pathways. Radiation also promotes the polarization of M1 tumor-associated macrophages to the M2 phenotype, which suppresses the anti-tumor immune response, whereas M1 macrophage–derived exosomes repolarize the M2 phenotype to the M1 phenotype, reshaping the tumor immunosuppressive microenvironment and improving the efficacy of radiation therapy. M1: M1-type tumor-associated macrophages (anti-tumor), M2: M2-type tumor-associated macrophages (pro-tumor), miRNAs: micro-RNAs, lncRNAs: long non-coding RNAs, circRNA: circular RNA, mRNA: messenger RNA
Fig. 5 The role of exosomes in cancer radiotherapy resistance. Radiation-induced paracrine effects mediated by exosomes and their contents (e.g., exosomal proteins and non-coding RNAs) affect radiotherapy efficacy via different pathways. Radiation also promotes the polarization of M1 tumor-associated macrophages to the M2 phenotype, which suppresses the anti-tumor immune response, whereas M1 macrophage–derived exosomes repolarize the M2 phenotype to the M1 phenotype, reshaping the tumor immunosuppressive microenvironment and improving the efficacy of radiation therapy. M1: M1-type tumor-associated macrophages (anti-tumor), M2: M2-type tumor-associated macrophages (pro-tumor), miRNAs: micro-RNAs, lncRNAs: long non-coding RNAs, circRNA: circular RNA, mRNA: messenger RNACC BY · PubMed Central
Fig. 6 Pathways promoting iron-caused death, PUFA-PL synthesis, the GPX4 and FSP1-CoQ signaling axes, and iron metabolism. Iron-caused death facilitates increased radiosensitivity (high expression in the blue areas), and inhibition of iron-caused death helps cancer cells acquire radioresistance (high expression in the purple areas). ACSL4: acyl coenzyme A synthetase long chain family member 4, LPCAT3: lysophosphatidylcholine acyltransferase 3, POR: cytochrome P450 oxidoreductase, ATM: ataxia-telangiectasia mutated, FSP1: ferroptosis suppressor protein 1, Cys: cysteine, GSH: glutathione, GPX4: glutathione peroxidase 4, PUFA-PL: polyunsaturated fatty acid- containing phospholipid, ROS: reactive oxygen species, CoQ: ubiquinone, SLC7A11: solute carrier family 7 member 11, LPCAT3: lysophosphatidylcholine acyltransferase 3, SLC3A2: Solute Carrier Family 3 member 2, PUFA: polyunsaturated fatty acid, CoQH2: ubiquinol, ALOX: lipoxygenase
Fig. 6 Pathways promoting iron-caused death, PUFA-PL synthesis, the GPX4 and FSP1-CoQ signaling axes, and iron metabolism. Iron-caused death facilitates increased radiosensitivity (high expression in the blue areas), and inhibition of iron-caused death helps cancer cells acquire radioresistance (high expression in the purple areas). ACSL4: acyl coenzyme A synthetase long chain family member 4, LPCAT3: lysophosphatidylcholine acyltransferase 3, POR: cytochrome P450 oxidoreductase, ATM: ataxia-telangiectasia mutated, FSP1: ferroptosis suppressor protein 1, Cys: cysteine, GSH: glutathione, GPX4: glutathione peroxidase 4, PUFA-PL: polyunsaturated fatty acid- containing phospholipid, ROS: reactive oxygen species, CoQ: ubiquinone, SLC7A11: solute carrier family 7 member 11, LPCAT3: lysophosphatidylcholine acyltransferase 3, SLC3A2: Solute Carrier Family 3 member 2, PUFA: polyunsaturated fatty acid, CoQH2: ubiquinol, ALOX: lipoxygenaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 232

  1. Krzyszczyk P, Acevedo A, Davidoff EJ, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3–4):79–100. https://doi.org/10.1142/S2339547818300020. · DOI
  2. Larionova I, Rakina M, Ivanyuk E, Trushchuk Y, Chernyshova A, Denisov E. Radiotherapy resistance: identifying universal biomarkers for various human cancers. J Cancer Res Clin Oncol. 2022;148(5):1015–31. https://doi.org/10.1007/s00432-022-03923-4. · DOI
  3. Chandra RA, Keane FK, Voncken FEM, Thomas CR Jr. Contemporary radiotherapy: present and future. Lancet. 2021;398(10295):171–84. https://doi.org/10.1016/S0140-6736(21)00233-6. · DOI
  4. Kumari N, Raghavan SC. G-quadruplex DNA structures and their relevance in radioprotection. Biochim Biophys Acta Gen Subj. 2021;1865(5):129857. https://doi.org/10.1016/j.bbagen.2021.129857. · DOI
  5. Balmukhanov SB, Yefimov ML, Kleinbock TS. Acquired radioresistance of tumour cells. Nature. 1967;216(5116):709–11. https://doi.org/10.1038/216709a0. · DOI
  6. Kim W, Youn H, Kang C, Youn B. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis. 2015;20(9):1242–52. https://doi.org/10.1007/s10495-015-1141-1. · DOI
  7. Yard BD, Adams DJ, Chie EK, et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016;7:11428. Published 2016 Apr 25. https://doi.org/10.1038/ncomms11428. · DOI
  8. Olivares-Urbano MA, Griñán-Lisón C, Marchal JA, Núñez MI. CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer. Cells. 2020;9(7):1651. Published 2020 Jul 9. https://doi.org/10.3390/cells9071651. · DOI
  9. Kabakov AE, Yakimova AO. Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing. Cancers (Basel). 2021;13(5):1102. Published 2021 Mar 4. https://doi.org/10.3390/cancers13051102. · DOI
  10. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247–54. https://doi.org/10.1038/85798. · DOI · Paper page
  11. Fojta M, Daňhel A, Havran L, Vyskočil V. Recent progress in electrochemical sensors and assays for DNA damage and repair. TrAC Trends Anal Chem. 2016;79:160–7. https://doi.org/10.1016/j.trac.2015.11.018. · DOI
  12. Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol Cell. 2017;66(6):801–17. https://doi.org/10.1016/j.molcel.2017.05.015. · DOI
  13. Ho V, Chung L, Singh A, et al. Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis. BMC Cancer. 2018;18(1):869. Published 2018 Sep 3. https://doi.org/10.1186/s12885-018-4776-9. · DOI
  14. Podhorecka M, Skladanowski A, Bozko P. H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. J Nucleic Acids. 2010;2010:920161. Published 2010 Aug 3. https://doi.org/10.4061/2010/920161. · DOI
  15. Borràs M, Armengol G, De Cabo M, Barquinero JF, Barrios L. Comparison of methods to quantify histone H2AX phosphorylation and its usefulness for prediction of radiosensitivity. Int J Radiat Biol. 2015;91(12):915–24. https://doi.org/10.3109/09553002.2015.1101501. · DOI
  16. Pucci S, Polidoro C, Joubert A, et al. Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2017;97(2):381–8. https://doi.org/10.1016/j.ijrobp.2016.10.018. · DOI
  17. Baptistella AR, Landemberger MC, Dias MVS, et al. Rab5C enhances resistance to ionizing radiation in rectal cancer. J Mol Med (Berl). 2019;97(6):855–69. https://doi.org/10.1007/s00109-019-01760-6. · DOI
  18. Zhang Q, Karnak D, Tan M, Lawrence TS, Morgan MA, Sun Y. FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell. 2016;61(3):419–33. https://doi.org/10.1016/j.molcel.2015.12.010. · DOI
  19. Jette N, Lees-Miller SP. The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis. Prog Biophys Mol Biol. 2015;117(2–3):194–205. https://doi.org/10.1016/j.pbiomolbio.2014.12.003. · DOI
  20. Ghelli Luserna di Rora' A, Iacobucci I, Martinelli G. The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol. 2017;10(1):77. Published 2017 Mar 29. https://doi.org/10.1186/s13045-017-0443-x. · DOI
  21. Li J, Yang CX, Mei ZJ, et al. Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation. Asian Pac J Cancer Prev. 2013;14(10):5725–30. https://doi.org/10.7314/apjcp.2013.14.10.5725. · DOI
  22. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352–5. https://doi.org/10.1126/science.1140735. · DOI · Paper page
  23. Larsen BD, Benada J, Yung PYK, et al. Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress. Science. 2022;376(6592):476–83. https://doi.org/10.1126/science.abi6378. · DOI
  24. Paull TT. Mechanisms of ATM Activation. Annu Rev Biochem. 2015;84:711–38. https://doi.org/10.1146/annurev-biochem-060614-034335. · DOI
  25. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160–6. https://doi.org/10.1126/science.1140321. · DOI · Paper page
  26. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci. 2006;31(7):402–10. https://doi.org/10.1016/j.tibs.2006.05.004. · DOI
  27. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124–38. https://doi.org/10.1016/j.pharmthera.2014.12.001. · DOI
  28. Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M. BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol. 2002;56(1):43–9. https://doi.org/10.1023/a:1014448721327. · DOI
  29. Ma R, Zhao LN, Yang H, et al. RNA binding motif protein 3 (RBM3) drives radioresistance in nasopharyngeal carcinoma by reducing apoptosis via the PI3K/AKT/Bcl-2 signaling pathway. Am J Transl Res. 2018;10(12):4130–4140. Published 2018 Dec 15.
  30. Ferris RL, Harrington K, Schoenfeld JD, et al. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treat Rev. 2023;113:102492. https://doi.org/10.1016/j.ctrv.2022.102492. · DOI
  31. Lee JU, Hosotani R, Wada M, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer. 1999;35(9):1374–80. https://doi.org/10.1016/s0959-8049(99)00134-3. · DOI
  32. Zhang L, Lu Z, Zhao X. Targeting Bcl-2 for cancer therapy. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188569. https://doi.org/10.1016/j.bbcan.2021.188569. · DOI
  33. Liang H, Deng L, Hou Y, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017;8(1):1736. Published 2017 Nov 23. https://doi.org/10.1038/s41467-017-01566-5. · DOI
  34. Li JY, Zhao Y, Gong S, et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat Commun. 2023;14(1):865. Published 2023 Feb 16. https://doi.org/10.1038/s41467-023-36523-y. · DOI
  35. Du SS, Chen GW, Yang P, et al. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Int J Radiat Oncol Biol Phys. 2022;112(5):1243–55. https://doi.org/10.1016/j.ijrobp.2021.12.162. · DOI
  36. Wang NH, Lei Z, Yang HN, et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann Transl Med. 2022;10(24):1406. https://doi.org/10.21037/atm-22-6049. · DOI
  37. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95. https://doi.org/10.1172/JCI67313. · DOI
  38. Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–51. https://doi.org/10.1038/s41591-018-0232-2. · DOI · Paper page
  39. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369–80. https://doi.org/10.1016/j.ccr.2005.10.012. · DOI · Paper page
  40. De Martino M, Daviaud C, Diamond JM, et al. Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer. Cancer Immunol Res. 2021;9(1):89–102. https://doi.org/10.1158/2326-6066.CIR-19-0305. · DOI
  41. Kalbasi A, Komar C, Tooker GM, et al. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017;23(1):137–48. https://doi.org/10.1158/1078-0432.CCR-16-0870. · DOI
  42. Vaupel P, Multhoff G. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities. Adenosine kann Strahlentherapie-vermittelte Immunantworten gegen Tumore konterkarieren. Strahlenther Onkol. 2016;192(5):279–287. https://doi.org/10.1007/s00066-016-0948-1. · DOI
  43. Nixon BG, Gao S, Wang X, Li MO. TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective [published online ahead of print, 2022 Nov 15]. Nat Rev Immunol. 2022;https://doi.org/10.1038/s41577-022-00796-z. · DOI
  44. Hardee ME, Marciscano AE, Medina-Ramirez CM, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res. 2012;72(16):4119–29. https://doi.org/10.1158/0008-5472.CAN-12-0546. · DOI
  45. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98–101.
  46. Shi R, Tang YQ, Miao H. Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm (2020). 2020;1(1):47–68. Published 2020 Jun 3. https://doi.org/10.1002/mco2.6. · DOI
  47. Arneth B. Tumor Microenvironment. Medicina (Kaunas). 2019;56(1):15. Published 2019 Dec 30. https://doi.org/10.3390/medicina56010015. · DOI
  48. Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901–14. https://doi.org/10.1016/j.trecan.2022.07.002. · DOI
  49. Chajon E, Castelli J, Marsiglia H, De Crevoisier R. The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. Crit Rev Oncol Hematol. 2017;111:124–32. https://doi.org/10.1016/j.critrevonc.2017.01.017. · DOI
  50. Shevtsov M, Sato H, Multhoff G, Shibata A. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. Front Oncol. 2019;9:156. Published 2019 Mar 19. https://doi.org/10.3389/fonc.2019.00156. · DOI
  51. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell. 2004;5(5):405–6. https://doi.org/10.1016/s1535-6108(04)00118-7. · DOI
  52. Wang H, Jiang H, Van De Gucht M, De Ridder M. Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?. Cancers (Basel). 2019;11(1):112. Published 2019 Jan 18. https://doi.org/10.3390/cancers11010112. · DOI
  53. Kotsafti A, Scarpa M, Castagliuolo I, Scarpa M. Reactive Oxygen Species and Antitumor Immunity-From Surveillance to Evasion. Cancers (Basel). 2020;12(7):1748. Published 2020 Jul 1. https://doi.org/10.3390/cancers12071748. · DOI
  54. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009;107(6):1053–62. https://doi.org/10.1002/jcb.22214. · DOI
  55. Yoshimura M, Itasaka S, Harada H, Hiraoka M. Microenvironment and radiation therapy. Biomed Res Int. 2013;2013:685308. https://doi.org/10.1155/2013/685308. · DOI
  56. Saunders M, Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer Suppl. 1996;27:S271–8.
  57. Brand A, Singer K, Koehl GE, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016;24(5):657–71. https://doi.org/10.1016/j.cmet.2016.08.011. · DOI · Paper page
  58. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31. https://doi.org/10.1056/NEJMoa1112824. · DOI
  59. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803. https://doi.org/10.1016/S1470-2045(15)00054-6. · DOI
  60. Feng H, Wang J, Chen W, et al. Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance. J Bone Oncol. 2016;5(2):67–73. Published 2016 Mar 9. https://doi.org/10.1016/j.jbo.2016.03.001. · DOI
  61. Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70. Published 2019 Mar 30. https://doi.org/10.1186/s12943-019-0994-2. · DOI
  62. Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S. SnapShot: CGAS-STING Signaling. Cell. 2018;173(1):276-276.e1. https://doi.org/10.1016/j.cell.2018.03.015. · DOI
  63. Huang Z, Wang Y, Yao D, Wu J, Hu Y, Yuan A. Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. Nat Commun. 2021;12(1):145. Published 2021 Jan 8. https://doi.org/10.1038/s41467-020-20243-8. · DOI
  64. O’Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol. 2009;19(2):71–7. https://doi.org/10.1016/j.semradonc.2008.11.001. · DOI
  65. Hittelman WN, Liao Y, Wang L, Milas L. Are cancer stem cells radioresistant? Future Oncol. 2010;6:1563–76. https://doi.org/10.2217/fon.10.121. · DOI
  66. Chang JC. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore). 2016;95(1 Suppl 1):S20–5. https://doi.org/10.1097/MD.0000000000004766. · DOI · Paper page
  67. Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013;341(1):63–72. https://doi.org/10.1016/j.canlet.2012.11.019. · DOI
  68. Skvortsov S, Debbage P, Lukas P, Skvortsova I. Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Semin Cancer Biol. 2015;31:36–42. https://doi.org/10.1016/j.semcancer.2014.06.002. · DOI
  69. Dando I, Cordani M, Dalla Pozza E, Biondani G, Donadelli M, Palmieri M. Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells. Oxid Med Cell Longev. 2015;2015:425708. https://doi.org/10.1155/2015/425708. · DOI
  70. Lei Y, Zhang D, Yu J, Dong H, Zhang J, Yang S. Targeting autophagy in cancer stem cells as an anticancer therapy [published correction appears in Cancer Lett. 2018 Jan 4;:]. Cancer Lett. 2017;393:33–39. https://doi.org/10.1016/j.canlet.2017.02.012. · DOI
  71. Yang G, Lu C, Mei Z, et al. Association of Cancer Stem Cell Radio-Resistance Under Ultra-High Dose Rate FLASH Irradiation With Lysosome-Mediated Autophagy. Front Cell Dev Biol. 2021;9:672693. Published 2021 Apr 29. https://doi.org/10.3389/fcell.2021.672693. · DOI
  72. Chen Y, Li D, Wang D, et al. Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells [published correction appears in J Cell Biochem. 2021 Feb;122(2):301–302]. J Cell Biochem. 2012;113(12):3643–3652. https://doi.org/10.1002/jcb.24228. · DOI
  73. Anding AL, Baehrecke EH. Cleaning House: Selective Autophagy of Organelles. Dev Cell. 2017;41(1):10–22. https://doi.org/10.1016/j.devcel.2017.02.016. · DOI · Paper page
  74. Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22(3):377–88. https://doi.org/10.1038/cdd.2014.150. · DOI · Paper page
  75. Hou J, Han ZP, Jing YY, et al. Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. Cell Death Dis. 2013;4(10):e844. Published 2013 Oct 10. https://doi.org/10.1038/cddis.2013.338. · DOI
  76. Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. Published 2020 Feb 7. https://doi.org/10.1038/s41392-020-0110-5. · DOI
  77. Cojoc M, Peitzsch C, Kurth I, et al. Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. Cancer Res. 2015;75(7):1482–94. https://doi.org/10.1158/0008-5472.CAN-14-1924. · DOI
  78. Angulo P, Kaushik G, Subramaniam D, et al. Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol. 2017;10(1):10. Published 2017 Jan 7. https://doi.org/10.1186/s13045-016-0373-z. · DOI
  79. Yao Z, Han L, Chen Y, et al. Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma. Cell Death Dis. 2018;9(6):701. Published 2018 Jun 13. https://doi.org/10.1038/s41419-018-0647-1. · DOI
  80. Sharma RA, Plummer R, Stock JK, et al. Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol. 2016;13(10):627–42. https://doi.org/10.1038/nrclinonc.2016.79. · DOI
  81. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett. 2012;327(1–2):48–60. https://doi.org/10.1016/j.canlet.2011.12.012. · DOI
  82. Li J, Sun H, Huang Y, Wang Y, Liu Y, Chen X. Pathways and assays for DNA double-strand break repair by homologous recombination. Acta Biochim Biophys Sin (Shanghai). 2019;51(9):879–89. https://doi.org/10.1093/abbs/gmz076. · DOI
  83. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18(1):99–113. https://doi.org/10.1038/cr.2008.1. · DOI
  84. Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16(1):20–33. https://doi.org/10.1038/nrc.2015.2. · DOI · Paper page
  85. Gavande NS, VanderVere-Carozza PS, Hinshaw HD, et al. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther. 2016;160:65–83. https://doi.org/10.1016/j.pharmthera.2016.02.003. · DOI
  86. Wang X, Ran T, Zhang X, et al. 3.9 Å structure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP. Science. 2017;358(6367):1206–1209. https://doi.org/10.1126/science.aan8414. · DOI
  87. Bharati BK, Gowder M, Zheng F, et al. Crucial role and mechanism of transcription-coupled DNA repair in bacteria. Nature. 2022;604(7904):152–9. https://doi.org/10.1038/s41586-022-04530-6. · DOI
  88. Caston RA, Gampala S, Armstrong L, Messmann RA, Fishel ML, Kelley MR. The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease. Drug Discov Today. 2021;26(1):218–28. https://doi.org/10.1016/j.drudis.2020.10.015. · DOI
  89. Lu H, Saha J, Beckmann PJ, Hendrickson EA, Davis AJ. DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response. Nucleic Acids Res. 2019;47(18):9467–79. https://doi.org/10.1093/nar/gkz694. · DOI
  90. Riballo E, Doherty AJ, Dai Y, et al. Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity. J Biol Chem. 2001;276(33):31124–32. https://doi.org/10.1074/jbc.M103866200. · DOI
  91. Herrero AB, San Miguel J, Gutierrez NC. Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability. PLoS One. 2015;10(3):e0121581. Published 2015 Mar 19. https://doi.org/10.1371/journal.pone.0121581. · DOI
  92. Fang X, Huang Z, Zhai K, et al. Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice. Sci Transl Med. 2021;13(600):eabc7275. https://doi.org/10.1126/scitranslmed.abc7275. · DOI
  93. Wang YH, Guo Z, An L, et al. LINC-PINT impedes DNA repair and enhances radiotherapeutic response by targeting DNA-PKcs in nasopharyngeal cancer. Cell Death Dis. 2021;12(5):454. Published 2021 May 7. https://doi.org/10.1038/s41419-021-03728-2. · DOI
  94. Guo Z, Wang YH, Xu H, et al. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma. Cell Death Dis. 2021;12(1):69. Published 2021 Jan 4. https://doi.org/10.1038/s41419-020-03302-2. · DOI
  95. Zenke FT, Zimmermann A, Sirrenberg C, et al. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. Mol Cancer Ther. 2020;19(5):1091–101. https://doi.org/10.1158/1535-7163.MCT-19-0734. · DOI
  96. Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019;10(1):5065. Published 2019 Nov 7. https://doi.org/10.1038/s41467-019-12836-9. · DOI
  97. Wu C, Williams TM, Robb R, et al. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020;26(13):3117–25. https://doi.org/10.1158/1078-0432.CCR-19-4193. · DOI
  98. Estrada-Bernal A, Chatterjee M, Haque SJ, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015;14(23):3713–24. https://doi.org/10.1080/15384101.2015.1104437. · DOI
  99. Wei F, Yan J, Tang D, et al. Inhibition of ERK activation enhances the repair of double-stranded breaks via non-homologous end joining by increasing DNA-PKcs activation. Biochim Biophys Acta. 2013;1833(1):90–100. https://doi.org/10.1016/j.bbamcr.2012.10.016. · DOI
  100. Ouellette MM, Zhou S, Yan Y. Cell Signaling Pathways That Promote Radioresistance of Cancer Cells. Diagnostics (Basel). 2022;12(3):656. Published 2022 Mar 8. https://doi.org/10.3390/diagnostics12030656. · DOI
  101. Mansour WY, Rhein T, Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res. 2010;38(18):6065–77. https://doi.org/10.1093/nar/gkq387. · DOI
  102. Cheng Q, Barboule N, Frit P, et al. Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res. 2011;39(22):9605–19. https://doi.org/10.1093/nar/gkr656. · DOI
  103. Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19(10):711–36. https://doi.org/10.1038/s41573-020-0076-6. · DOI
  104. Noordermeer SM, van Attikum H. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells. Trends Cell Biol. 2019;29(10):820–34. https://doi.org/10.1016/j.tcb.2019.07.008. · DOI
  105. Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40. https://doi.org/10.1093/annonc/mdt384. · DOI
  106. Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2020;19(1):23–38. https://doi.org/10.1038/s41573-019-0046-z. · DOI
  107. Gani C, Coackley C, Kumareswaran R, et al. In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiother Oncol. 2015;116(3):486–94. https://doi.org/10.1016/j.radonc.2015.08.003. · DOI
  108. Pant S, Maitra A, Yap TA. PARP inhibition - opportunities in pancreatic cancer. Nat Rev Clin Oncol. 2019;16(10):595–6. https://doi.org/10.1038/s41571-019-0257-6. · DOI
  109. Loap P, Loirat D, Berger F, et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022;8(12):1802–8. https://doi.org/10.1001/jamaoncol.2022.5074. · DOI
  110. Bi Y, Verginadis II, Dey S, et al. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. Gynecol Oncol. 2018;150(3):534–44. https://doi.org/10.1016/j.ygyno.2018.07.002. · DOI
  111. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154–64. https://doi.org/10.1056/NEJMoa1611310. · DOI
  112. Jannetti SA, Carlucci G, Carney B, et al. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. J Nucl Med. 2018;59(8):1225–33. https://doi.org/10.2967/jnumed.117.205054. · DOI
  113. Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012;30(6):2113–20. https://doi.org/10.1007/s10637-011-9770-x. · DOI
  114. Wilson A, Menon V, Khan Z, Alam A, Litovchick L, Yakovlev V. Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation. Redox Biol. 2019;24:101169. https://doi.org/10.1016/j.redox.2019.101169. · DOI
  115. Harashima H, Dissmeyer N, Schnittger A. Cell cycle control across the eukaryotic kingdom. Trends Cell Biol. 2013;23(7):345–56. https://doi.org/10.1016/j.tcb.2013.03.002. · DOI
  116. Fu H, Wu ZX, Lei ZN, et al. The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Front Pharmacol. 2022;13:861642. Published 2022 Mar 8. https://doi.org/10.3389/fphar.2022.861642. · DOI
  117. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis. 2006;21(1):3–9. https://doi.org/10.1093/mutage/gei063. · DOI
  118. Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ. 2001;8(11):1052–65. https://doi.org/10.1038/sj.cdd.4400874. · DOI
  119. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1(3):179–86. https://doi.org/10.1038/35043058. · DOI · Paper page
  120. Hirao A, Cheung A, Duncan G, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol. 2002;22(18):6521–32. https://doi.org/10.1128/MCB.22.18.6521-6532.2002. · DOI
  121. Jin MH, Oh DY. ATM in DNA repair in cancer. Pharmacol Ther. 2019;203:107391. https://doi.org/10.1016/j.pharmthera.2019.07.002. · DOI
  122. Stewart-Ornstein J, Iwamoto Y, Miller MA, et al. p53 dynamics vary between tissues and are linked with radiation sensitivity. Nat Commun. 2021;12(1):898. Published 2021 Feb 9. https://doi.org/10.1038/s41467-021-21145-z. · DOI
  123. Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. Cell Rep. 2020;30(2):497-509.e4. https://doi.org/10.1016/j.celrep.2019.12.032. · DOI
  124. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417. https://doi.org/10.1038/s41571-020-0341-y. · DOI
  125. Shu HK, Kim MM, Chen P, Furman F, Julin CM, Israel MA. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci U S A. 1998;95(24):14453–8. https://doi.org/10.1073/pnas.95.24.14453. · DOI
  126. Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer. 2002;100(4):472–5. https://doi.org/10.1002/ijc.10503. · DOI
  127. Jackson MR, Ashton M, Koessinger AL, Dick C, Verheij M, Chalmers AJ. Mesothelioma Cells Depend on the Antiapoptotic Protein Bcl-xL for Survival and Are Sensitized to Ionizing Radiation by BH3-Mimetics. Int J Radiat Oncol Biol Phys. 2020;106(4):867–77. https://doi.org/10.1016/j.ijrobp.2019.11.029. · DOI
  128. Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev. 2016;36(2):313–41. https://doi.org/10.1002/med.21379. · DOI
  129. Lopez A, Reyna DE, Gitego N, et al. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun. 2022;13(1):1199. Published 2022 Mar 7. https://doi.org/10.1038/s41467-022-28741-7. · DOI
  130. Lin F, Luo J, Gao W, et al. COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol. 2013;34(5):2817–26. https://doi.org/10.1007/s13277-013-0840-x. · DOI
  131. Shonai T, Adachi M, Sakata K, et al. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ. 2002;9(9):963–71. https://doi.org/10.1038/sj.cdd.4401050. · DOI
  132. Liao J, Jin H, Li S, et al. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):454. Published 2019 Nov 6. https://doi.org/10.1186/s13046-019-1419-1. · DOI
  133. Ciccarelli C, Di Rocco A, Gravina GL, et al. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. J Cancer Res Clin Oncol. 2018;144(9):1685–99. https://doi.org/10.1007/s00432-018-2696-3. · DOI
  134. Zhou W, Xu J, Li H, et al. Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage. Clin Cancer Res. 2017;23(4):1104–16. https://doi.org/10.1158/1078-0432.CCR-16-1585. · DOI
  135. Xu T, Ma Q, Li Y, et al. A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer. Signal Transduct Target Ther. 2022;7(1):354. Published 2022 Oct 17. https://doi.org/10.1038/s41392-022-01182-w. · DOI
  136. Hrdinka M, Yabal M. Inhibitor of apoptosis proteins in human health and disease. Genes Immun. 2019;20(8):641–50. https://doi.org/10.1038/s41435-019-0078-8. · DOI
  137. Rödel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005;65(11):4881–7. https://doi.org/10.1158/0008-5472.CAN-04-3028. · DOI
  138. Sun XS, Tao Y, Le Tourneau C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020;21(9):1173–87. https://doi.org/10.1016/S1470-2045(20)30327-2. · DOI
  139. Bourhis J, Burtness B, Licitra LF, et al. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022;18(14):1669–78. https://doi.org/10.2217/fon-2021-1634. · DOI
  140. Zhou S, Zhang M, Zhou C, Wang W, Yang H, Ye W. The role of epithelial-mesenchymal transition in regulating radioresistance. Crit Rev Oncol Hematol. 2020;150:102961. https://doi.org/10.1016/j.critrevonc.2020.102961. · DOI
  141. Takala H, Saarnio J, Wiik H, Ohtonen P, Soini Y. HIF-1α and VEGF are associated with disease progression in esophageal carcinoma. J Surg Res. 2011;167(1):41–8. https://doi.org/10.1016/j.jss.2009.11.725. · DOI
  142. Yi M, Ban Y, Tan Y, Xiong W, Li G, Xiang B. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer. Mol Metab. 2019;20:1–13. https://doi.org/10.1016/j.molmet.2018.11.013. · DOI
  143. Huang R, & Zhou PK. HIF-1 signaling: A key orchestrator of cancer radioresistance. Radiation Medicine and Protection. https://doi.org/10.1016/j.radmp.2020.01.006. · DOI
  144. Yang X, Lu Y, Hang J, et al. Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. Cancer Immunol Res. 2020;8(11):1440–51. https://doi.org/10.1158/2326-6066.CIR-20-0111. · DOI
  145. Colwell N, Larion M, Giles AJ, et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 2017;19(7):887–96. https://doi.org/10.1093/neuonc/now258. · DOI
  146. Zhang Y, Liu X, Zeng L, et al. Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment. Br J Cancer. 2022;127(10):1760–72. https://doi.org/10.1038/s41416-022-01956-7. · DOI
  147. Mayer R, Hamilton-Farrell MR, van der Kleij AJ, et al. Hyperbaric oxygen and radiotherapy. Strahlenther Onkol. 2005;181(2):113–23. https://doi.org/10.1007/s00066-005-1277-y. · DOI
  148. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30(15):1777–83. https://doi.org/10.1200/JCO.2011.35.9315. · DOI
  149. Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev. 2018;4(4):CD005007. Published 2018 Apr 11. https://doi.org/10.1002/14651858.CD005007.pub4. · DOI
  150. Urtasun R, Feldstein ML, Partington J, et al. Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer. 1982;46(1):101–8. https://doi.org/10.1038/bjc.1982.171. · DOI
  151. Thomson D, Yang H, Baines H, et al. NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol (R Coll Radiol). 2014;26(6):344–7. https://doi.org/10.1016/j.clon.2014.03.003. · DOI
  152. Meng L, Cheng Y, Tong X, et al. Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects. ACS Nano. 2018;12(8):8308–22. https://doi.org/10.1021/acsnano.8b03590. · DOI
  153. Kuzet SE, Gaggioli C. Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res. 2016;365(3):607–19. https://doi.org/10.1007/s00441-016-2467-x. · DOI
  154. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. https://doi.org/10.1038/s41573-018-0004-1. · DOI
  155. Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev. 2021;101(1):147–76. https://doi.org/10.1152/physrev.00048.2019. · DOI · Paper page
  156. Goulet CR, Champagne A, Bernard G, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):137. Published 2019 Feb 11. https://doi.org/10.1186/s12885-019-5353-6. · DOI
  157. Zhan Y, Du J, Min Z, et al. Carcinoma-associated fibroblasts derived exosomes modulate breast cancer cell stemness through exonic circHIF1A by miR-580–5p in hypoxic stress. Cell Death Discov. 2021;7(1):141. Published 2021 Jun 12. https://doi.org/10.1038/s41420-021-00506-z. · DOI
  158. Ren J, Ding L, Zhang D, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932–3948. Published 2018 Jun 24. https://doi.org/10.7150/thno.25541. · DOI · Paper page
  159. Zhang H, Yue J, Jiang Z, et al. CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma. Cell Death Dis. 2017;8(5):e2790. Published 2017 May 18. https://doi.org/10.1038/cddis.2017.180. · DOI
  160. Zhang H, Hua Y, Jiang Z, et al. Cancer-associated Fibroblast-promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2019;25(6):1989–2000. https://doi.org/10.1158/1078-0432.CCR-18-0773. · DOI
  161. Nicolas AM, Pesic M, Engel E, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022;40(2):168-184.e13. https://doi.org/10.1016/j.ccell.2022.01.004. · DOI · Paper page
  162. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001. https://doi.org/10.4161/cc.8.23.10238. · DOI · Paper page
  163. Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. Published 2021 Oct 11. https://doi.org/10.1186/s12943-021-01428-1. · DOI · Paper page
  164. Zhang R, Qi F, Zhao F, et al. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis. 2019;10(4):273. Published 2019 Mar 20. https://doi.org/10.1038/s41419-019-1435-2. · DOI · Paper page
  165. Gunaydin G, Kesikli SA, Guc D. Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset. Oncoimmunology. 2015;4(9):e1034918. Published 2015 May 27. https://doi.org/10.1080/2162402X.2015.1034918. · DOI
  166. Li MO, Wolf N, Raulet DH, et al. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021;39(6):725–9. https://doi.org/10.1016/j.ccell.2021.05.016. · DOI
  167. Lan Y, Moustafa M, Knoll M, et al. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39(10):1388-1403.e10. https://doi.org/10.1016/j.ccell.2021.08.008. · DOI
  168. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol. 2013;108(3):378–87. https://doi.org/10.1016/j.radonc.2013.06.003. · DOI
  169. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–34. https://doi.org/10.1038/nm.4409. · DOI · Paper page
  170. Liu Z, Wu K, Gu S, et al. A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma [published correction appears in Clin Transl Med. 2022 Jun;12(6):e741]. Clin Transl Med. 2021;11(9):e545. https://doi.org/10.1002/ctm2.545. · DOI
  171. Schulz A, Meyer F, Dubrovska A, Borgmann K. Cancer Stem Cells and Radioresistance: DNA Repair and Beyond. Cancers (Basel). 2019;11(6):862. Published 2019 Jun 21. https://doi.org/10.3390/cancers11060862. · DOI
  172. Desai A, Webb B, Gerson SL. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother Oncol. 2014;110(3):538–45. https://doi.org/10.1016/j.radonc.2013.10.040. · DOI
  173. Zhang P, Wei Y, Wang L, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014;16(9):864–75. https://doi.org/10.1038/ncb3013. · DOI
  174. Wang X, Ma Z, Xiao Z, et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep. 2012;28(6):2247–54. https://doi.org/10.3892/or.2012.2068. · DOI
  175. Carruthers R, Ahmed SU, Strathdee K, et al. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Mol Oncol. 2015;9(1):192–203. https://doi.org/10.1016/j.molonc.2014.08.003. · DOI
  176. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature. 2012;488(7412):527–30. https://doi.org/10.1038/nature11344. · DOI
  177. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60. https://doi.org/10.1038/nature05236. · DOI
  178. Balbous A, Cortes U, Guilloteau K, et al. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells. BMC Cancer. 2016;16:604. Published 2016 Aug 5. https://doi.org/10.1186/s12885-016-2647-9. · DOI
  179. Szumiel I. Ionizing radiation-induced oxidative stress, epigenetic changes and genomic instability: the pivotal role of mitochondria. Int J Radiat Biol. 2015;91(1):1–12. https://doi.org/10.3109/09553002.2014.934929. · DOI
  180. Rothe K, Porter V, Jiang X. Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. Int J Mol Sci. 2019;20(3):461. Published 2019 Jan 22. https://doi.org/10.3390/ijms20030461. · DOI
  181. Digomann D, Linge A, Dubrovska A. SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed. Autophagy. 2019;15(10):1850–1. https://doi.org/10.1080/15548627.2019.1639302. · DOI
  182. Tsai CY, Ko HJ, Huang CF, et al. Ionizing Radiation Induces Resistant Glioblastoma Stem-Like Cells by Promoting Autophagy via the Wnt/β-Catenin Pathway. Life (Basel). 2021;11(5):451. Published 2021 May 18. https://doi.org/10.3390/life11050451. · DOI
  183. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71(3):634–639. https://doi.org/10.1158/0008-5472.CAN-10-3220. · DOI · Paper page
  184. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010;7(2):150–61. https://doi.org/10.1016/j.stem.2010.07.007. · DOI
  185. Schöning JP, Monteiro M, Gu W. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α. Clin Exp Pharmacol Physiol. 2017;44(2):153–61. https://doi.org/10.1111/1440-1681.12693. · DOI
  186. Peitzsch C, Perrin R, Hill RP, Dubrovska A, Kurth I. Hypoxia as a biomarker for radioresistant cancer stem cells. Int J Radiat Biol. 2014;90(8):636–52. https://doi.org/10.3109/09553002.2014.916841. · DOI
  187. Wang J, Wakeman TP, Lathia JD, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28(1):17–28. https://doi.org/10.1002/stem.261. · DOI
  188. Oren O, Smith BD. Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways. Stem Cell Rev Rep. 2017;13(1):17–23. https://doi.org/10.1007/s12015-016-9691-3. · DOI
  189. Nwabo Kamdje AH, Takam Kamga P, Tagne Simo R, et al. Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog. Cancer Biol Med. 2017;14(2):109–20. https://doi.org/10.20892/j.issn.2095-3941.2016.0032. · DOI
  190. Chatterjee S, Sil PC. Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy. Pharmacol Res. 2019;142:251–61. https://doi.org/10.1016/j.phrs.2019.02.027. · DOI
  191. Weinberg F, Ramnath N, Nagrath D. Reactive Oxygen Species in the Tumor Microenvironment: An Overview. Cancers (Basel). 2019;11(8):1191. Published 2019 Aug 16. https://doi.org/10.3390/cancers11081191. · DOI · Paper page
  192. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80. https://doi.org/10.1038/s41568-021-00378-6. · DOI
  193. Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377–92. https://doi.org/10.1007/s00018-015-2070-4. · DOI
  194. Shimura T, Noma N, Sano Y, et al. AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother Oncol. 2014;112(2):302–7. https://doi.org/10.1016/j.radonc.2014.07.015. · DOI
  195. Li L, Liu H, Du L, et al. miR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation. Oncol Res. 2018;26(4):547–56. https://doi.org/10.3727/096504017X15016337254605. · DOI
  196. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;356(2 Pt A):156–164. https://doi.org/10.1016/j.canlet.2014.04.001. · DOI
  197. Fang Y, Zhan Y, Xie Y, et al. Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology. 2022;75(6):1386–401. https://doi.org/10.1002/hep.32177. · DOI
  198. Sunami Y, Rebelo A, Kleeff J. Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. Cancers (Basel). 2017;10(1):3. Published 2017 Dec 23. https://doi.org/10.3390/cancers10010003. · DOI
  199. Bacci M, Lorito N, Smiriglia A, Morandi A. Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance. Trends Cancer. 2021;7(3):198–213. https://doi.org/10.1016/j.trecan.2020.10.004. · DOI
  200. Du Q, Tan Z, Shi F, et al. PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation. Cancer Sci. 2019;110(6):2050–62. https://doi.org/10.1111/cas.14011. · DOI

200 of 232 shown

Cited by

Sorted by citations

See all 527

Metadata

Authors
Wu, Y., Song, Y., Wang, R., & Wang, T.
Venue
Molecular Cancer
Publisher
Springer Science and Business Media LLC
Published
2023-06-15
Volume
22
Issue
1
ISSN
1476-4598
DOI
10.1186/s12943-023-01801-2
PMC
PMC10268375
Cited by
527
References
23
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review